# OnCo record bre12-158 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/bre12-158/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "bre12-158", "NCT02101385" ;
  schema:name "BRE12-158 (Hoosier Oncology Group)"@en ;
  schema:alternateName "BRE12-158"@en, "HCRN BRE12-158"@en ;
  schema:description "BRE12-158 sequenced the cancer left behind after pre-operative chemotherapy and matched a targeted drug to it. Matched therapy was no better than the doctor's usual choice, which increasingly meant capecitabine, and blood-borne tumour DNA after surgery predicted who relapsed."@en ;
  schema:url <https://onco.cc/trials/bre12-158/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02101385>, <https://doi.org/10.1200/JCO.21.01657> ;
  onco:status "negative" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/tnbc-residual-disease-decision/> ;
  onco:trials <https://onco.cc/trials/create-x/>, <https://onco.cc/trials/c-trak-tn/>, <https://onco.cc/trials/ea1131/> .